Ryoki Arimoto
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- COVID-19 Clinical Research Studies 6
-
- Chronic Kidney Disease and Diabetes 1
- Acute Kidney Injury Research 1
- Journals
- The Lancet (6 papers)Nephrology Dialysis Transplantation (1 paper)EClinicalMedicine (1 paper)Clinical Medicine (1 paper)
- Partner nations
- United KingdomGermanyVietnam
In The Last Decade
Ryoki Arimoto
9 papers receiving 1.6k citations
Ryoki Arimoto's Hit Papers
Peers
Comparison fields: 5 of 79
- Infectious Diseases 1.3k
- Applied Microbiology and Biotechnology 35
- Internal Medicine 27
- Statistics and Probability 46
- Oncology 76
Countries citing papers authored by Ryoki Arimoto
This map shows the geographic impact of Ryoki Arimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryoki Arimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryoki Arimoto more than expected).
Fields of papers citing papers by Ryoki Arimoto
This network shows the impact of papers produced by Ryoki Arimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryoki Arimoto. The network helps show where Ryoki Arimoto may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 7 | 2024 | 41 | |
| 8 | 2025 | 4 | |
| 9 | 2024 | 1 |
About Ryoki Arimoto
Ryoki Arimoto is a scholar working on Infectious Diseases, Nephrology, Endocrinology, Diabetes and Metabolism, Economics and Econometrics and Nuclear Energy and Engineering, having authored 9 papers that have together received 1.7k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers), Chronic Kidney Disease and Diabetes (1 paper), Diabetes Treatment and Management (1 paper), Hormonal Regulation and Hypertension (1 paper), Acute Kidney Injury Research (1 paper) and Health Systems, Economic Evaluations, Quality of Life (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (27 citations), Statistics and Probability (46 citations) and Oncology (76 citations). Ryoki Arimoto has collaborated with scholars based in United Kingdom, Germany and Vietnam. Their work appears in journals such as The Lancet, Nephrology Dialysis Transplantation, EClinicalMedicine and Clinical Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.